R. Blair Egerdie, BSc, MD, FRCSC

Urology Associates / Urologic Medical Research
Driftwood Centre

450 Westheights Drive, Suite 18

Kitchener, Ontario, Canada
N2N 2B9
519-578-0470 

 

Speciality: Urology

 

Dr. Blair Egerdie

Research Interests: Benign Prostatic Hyperplasia/ Bladder Outlet Obstruction, Bladder Cancer, Erectile Dysfunction, Interstitial Cystitis/Painful Bladder Syndrome, Overactive Bladder, Premature Ejaculation, Prostate Cancer, Prostatic Intraepithelial Neoplasia, Prostatitis/Chronic Pelvic Pain Syndrome, Urinary Incontinence

 

Dr. Blair Egerdie is a board certified urologist, and has been conducting clinical trials in urology since 1997.  He is a member of the Canadian, American, and European Urological Associations, as well as The Society of Urologic Oncology. He is also an Adjunct Professor of Urology at the University of Western Ontario. 

Dr. Egerdie is an invited lecturer to Urologists and other physicians throughout Canada, US, and Europe on topics relating to new developments in the field of Urology.

As the Principal Investigator for over 55 clinical trials, Dr. Egerdie has experience in Phase I -IV clinical trials in urology, for indications including overactive bladder (OAB), benign prostatic hyperplasia (BPH), prostate cancer, nocturia, and interstitial cystitis.

As a result of his work in clinical research, Dr. Egerdie's study results have been presented at medical conferences and published in journals such as the New England Journal of Medicine, European Urology, Urology, Journal of Urology, Canadian Urological Association Journal, British Journal of Urology International, and Urologic Radiology.

 

Click to view Dr. Blair Egerdie's Publications

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2017 Feb; 197(2S): S216-23. Epub 2016 Dec 22. PMID: 28012773 / doi: 10.1016/j.juro.2016.10.109

Denys P, Keppenne V, Kohan A, Egerdie B, Brucker B, Magyar A, Nicandro J, Jenkins B, Chartier-Kastler E. Efficacy and safety of onabotulinumtoxin A 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients. Prog Urol 2016 Nov; 26(13): 751. PMID: 27969264 / doi: 10.1016/j.purol.2016.07.170

Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. A phase II study of efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis/bladder pain syndrome. J Urol 2016 Sep; 196(3): 747-54. Epub 2016 Mar 9. PMID: 26968644 / doi: 10.1016/j.juro.2016.03.003

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer 2016 Mar; 24(3): 1327-37. Epub 2015 Sep 2. PMID: 26329397 / doi: 10.1007/s00520-015-2908-1

Everaert K, Gruenenfelder J, Schulte-Baukloh H, Egerdie RB, Khalaf K, Joshi M, Ni Q, Sussman D. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. Int J Urol 2015 Dec; 22(12):1131-7. Epub 2015 Sep 22. PMID: 26391359 / doi: 10.1111/iju.12912

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.  Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.  Support Care Cancer 2013 Dec; 21(12): 3497-507. Epub 2013 Aug 22. PMID: 23975226

Karsh LI, Egerdie RB, Albala DM, Flynn BJ.  The Transurethral Suprapubic endo-Cystostomy (T-SPeC): A Novel Suprapubic Catheter Insertion Device.  J Endourol 2013 Jul; 27(7):880-885. Epub 2013 May 28.  PMID: 23488708

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.  J Urol 2013 Jun; 189(6):2186-2193.  Epub 2012 Dec 14.  PMID: 23246476

Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study.  Eur Urol 2013 May; 63(5):927-935.  Epub 2012 Sep 11.  PMID: 23040208

Marberger M, Chartier-Kastier E, Egerdie B, Lee KS, Grosse J, Bugarin D, Zhou J, Patel A, Haag-Molkenteller C.  A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.  Eur Urol 2013 Mar; 63(3):496-503.  Epub 2012 Oct 12.  PMID: 23098762

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C.  Sarcopenia during androgen-deprivation therapy for prostate cancer.  J Clin Oncol 2012 Sep 10; 30(26):3271-3276.    Epub 2012 May 29.  PMID: 22649143

Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C.  Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.  Prostate Cancer Prostatic Dis 2012 Sep; 15(3):308-312.  PMID: 22641239

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.  Lancet 2012 Mar 24; 379(9821):1103-1111.  Epub 2012 Jan 24.  PMID: 22277570

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.  Lancet 2012 Jan 7; 379(9810):39-46.  Epub 2011 Nov 15.  PMID: 22093187

Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.  J Sex Med 2012 Jan; 9(1):271-281.  Epub 2011 Oct 7.  PMID: 21981682

Smith MR, Saad F, Egerdie B, Sieber P, Tammela TL, Leder BZ, Ke C, Goessl C.  Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.  J Bone Miner Res 2011 Dec; 26(12):2827-2833.  doi: 10.1002/jbmr.492.  PMID: 21898590

Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P.  Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.  Eur Urol 2011 May; 59(5):747-754.  Epub 2010 Nov 24.  PMID: 21129846

Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, Radomski S, Drutz H, Schulz J, Barkin J, Hirshberg E, Corcos J.  Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (? 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.  Curr Med Res Opin 2011 Feb; 27(2):375-382.  Epub 2010 Dec 23.  PMID: 21175373

Nickel JC, Egerdie RB, Steinhoff G, Palmer B, Hanno P.  A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome.  Urology 2010 Oct; 76(4):804-809.  Epub 2010 May 21.  PMID: 20494413

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.  Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.  J Urol 2010 May; 183(5):1892-1898.  Epub 2010 Mar 18.  PMID: 20303119

Egerdie B, Saad F.  Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.  Can Urol Assoc J 2010 Apr; 4(2):129-135.  PMID: 20368898

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.  Effect of dutasteride on the risk of prostate cancer.  N Engl J Med 2010 Apr 1; 362(13):1192-1202.  PMID: 20357281

Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C.  Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.  J Urol 2009 Dec; 182(6):2670-2676. PMID: 19836774 / doi: 10.1016/j.juro.2009.08.048

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.  N Engl J Med 2009 Aug 20; 361(8):745-755.  [Article 10.1056/NEJMoa0809003 published August 11, 2009 at NEJM.org]  PMID: 19671656

Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K.  A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis.  BJU Int 2009 Jan; 103(1):56-60.  Epub 2008 Sep 3. PMID: 18778342

Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S.  Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.  Eur Urol 2007 Jul; 52(1):106-115.  Epub 2007 Jan 16.  PMID: 17270340

Egerdie RB, Reid G, Trachtenberg J.  The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture.  J Urol 1989 Aug; 142(2 Pt 1):390-398.  PMID: 2501520

Klotz LH, Egerdie RB, Herschorn S.  Migrating suture masquerading as a renal pelvic carcinoma: an unusual complication of the Kock pouch.  Urol Radiol 1989; 11(2):100-101.  PMID: 2667247

Egerdie RB, Buckspan MB, Klotz PG, Steinhardt MI, Pritzker KP.  Bilateral multilocular renal cysts.  J Urol 1986 Feb; 135(2):346-348.  PMID: 3944873

Egerdie B, Singer M.  Morphology of gel state phosphatidylethanolamine and phosphatidylcholine liposomes: a negative stain electron microscopic study.  Chem Phys Lipids 1982 Aug; 31(1):75-85.  PMID: 7127614

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login